Clinical trial · Interventional
LMBA02 Protocol for Patients With a Burkitt Lymphoma
NCT00180882CI-TRIAL-00000435unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore in a multicenter international prospective randomized study (phase III) whether rituximab combined with the standard French LMB chemotherapy scheme results in a higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years with Burkitt lymphoma or ALL 3.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Burkitt Lymphoma | Burkitt Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| rituximab | Drug | Rituximab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Event free survival from date of first randomization
Secondary outcomes (1)
- measure
- Complete and partial response rate, overall survival, toxicity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age : 18 years or older * Histologically or cytologically proven Burkitt lymphoma according to the WHO classification * WHO performance \< 3 * Informed consent Exclusion Criteria: * Known HIV positive infection * Positive serology for HCV and HBV (except after vaccination) * Patients previously treated for lymphoma * cardiac disease that contradict anthracycline chemotherapy * Psychological or psychiatric condition who contradict steroids therapy * Patients with serious renal failure unrelated to the lymphoma (serum creatinin level higher than 150 mmole/L) * Cirrhosis or severe hepatic failure unrelated to the lymphoma * Previous malignant disease except basal cell skin carcinoma or in situ uterine cervix carcinoma * Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule * Primary organ transplant or other immunosuppressive conditions Pregnancy
References
Publications (1)
- DERIVEDRibrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker LM, Recher C, Ghesquieres H, Morschhauser F, Girault S, Le Gouill S, Ojeda-Uribe M, Mariette C, Cornillon J, Cartron G, Verge V, Chassagne-Clement C, Dombret H, Coiffier B, Lamy T, Tilly H, Salles G. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Jun 11;387(10036):2402-11. doi: 10.1016/S0140-6736(15)01317-3. Epub 2016 Apr 11. PMID 27080498